Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 12:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Prolia® Clear all

Conditions: Healthy
Interventions: Denosumab; Drug
Lead sponsor: Samsung Bioepis Co., Ltd.; Industry
Eligibility: 28 Years to 55 Years · Male only
Enrollment: 168 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Postmenopausal Women With Osteoporosis
Interventions: GP2411, EU-Prolia (EU-authorized Prolia®); Biological
Lead sponsor: Sandoz; Industry
Eligibility: 55 Years to 80 Years · Female only
Enrollment: 527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 6
States / cities: Peoria, Arizona • Miami, Florida • Wichita, Kansas + 3 more

Conditions: Cancer, Hematologic Malignancies, Multiple Myeloma, Oncology, Bone Metastases, Multiple Myeloma Bone Lesions
Interventions: Denosumab, Zoledronic acid, Placebo to Denosumab, Placebo to zoledronic acid, Denosumab (for the open-label treatment phase); Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 1,718 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 79
States / cities: Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 67 more

Conditions: Healthy Volunteers
Interventions: Bmab 1000, Prolia®; Biological
Lead sponsor: Biocon Biologics UK Ltd; Industry
Eligibility: 28 Years to 55 Years
Enrollment: 190 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Cancer, Cataract, Low Bone Mineral Density, Osteopenia, Osteoporosis, Prostate Cancer
Interventions: Denosumab, Placebo; Biological
Lead sponsor: Amgen; Industry
Eligibility: 30 Years to 120 Years · Male only
Enrollment: 769 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 52
States / cities: Anaheim, California • Laguna Hills, California • Murrieta, California + 45 more

Conditions: Healthy Volunteer
Interventions: Denosumab CP4, Denosumab CP2; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 146 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 2
States / cities: Cypress, California • San Antonio, Texas

Conditions: Steroid-induced Osteopor, Glucocorticoid-induced Ostepor
Interventions: Denosumab, Placebo for risendronate, Risendronate, Placebo for denosumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 795 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 18
States / cities: Birmingham, Alabama • Sacramento, California • Lakewood, Colorado + 14 more

Conditions: Osteoporosis, Postmenopausal
Interventions: TVB-009, Prolia®; Combination Product
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 60 Years to 90 Years · Female only
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 20
States / cities: Phoenix, Arizona • Tucson, Arizona • San Diego, California + 17 more

Conditions: Postmenopausal Osteoporosis
Interventions: Romosozumab, Placebo, Denosumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 55 Years to 90 Years · Female only
Enrollment: 7,180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 25
States / cities: Tucson, Arizona • Laguna Hills, California • Los Angeles, California + 22 more

Conditions: Postmenopausal Osteoporosis
Interventions: RGB-14-P, Prolia®; Drug
Lead sponsor: Gedeon Richter Plc.; Industry
Eligibility: 60 Years to 90 Years · Female only
Enrollment: 473 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Miami, Florida • Miami Lakes, Florida • Decatur, Georgia + 1 more

Conditions: Postmenopausal Osteoporosis
Interventions: Denosumab (CP2), Denosumab (CP4); Drug
Lead sponsor: Amgen; Industry
Eligibility: 55 Years to 100 Years · Female only
Enrollment: 394 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 10
States / cities: Santa Maria, California • South Lake Tahoe, California • Lakewood, Colorado + 7 more

Conditions: Osteoporosis
Interventions: denosumab, teriparatide; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 45 Years and older · Female only
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Placebo, Denosumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 4,509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 93
States / cities: Birmingham, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 81 more

Conditions: Post Menopausal Osteoporosis
Interventions: Denosumab, Zoledronic Acid, Placebo to Denosumab, Placebo to Zoledronic Acid; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 55 Years and older · Female only
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 9
States / cities: Santa Monica, California • Lakewood, Colorado • Longmont, Colorado + 6 more

Conditions: Postmenopausal Osteoporosis
Interventions: Teriparatide 40-mcg subcutaneous injection, Denosumab Injection, Alendronate Oral Tablet; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 45 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Early Stage Breast Cancer
Interventions: Denosumab; Drug
Lead sponsor: Hope Rugo, MD; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Postmenopausal, Osteopenia, Rheumatoid Arthritis, Osteoporosis
Interventions: Etanercept, Denosumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 45 Years to 80 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 2
States / cities: Duncansville, Pennsylvania • Dallas, Texas

Conditions: Osteoporosis, Age-Related
Interventions: Not listed
Lead sponsor: Amgen; Industry
Eligibility: Female only
Enrollment: 935 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 60
States / cities: Birmingham, Alabama • Chandler, Arizona • Peoria, Arizona + 57 more

Conditions: Diabetes Mellitus, Type 2, Osteoporosis
Interventions: Denosumab 60 mg/ml [Prolia], Placebo; Drug · Other
Lead sponsor: Mishaela Rubin; Other
Eligibility: 50 Years to 90 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity Study of SB16 in Healthy Male Subjects

Study Investigating PK, PD, Efficacy, Safety, and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal Osteoporosis

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Bmab 1000 and Prolia® in Normal Healthy Volunteers: DENARIUS: DENosumab Pharmacokinetic equivAlence tRIal in Healthy volUnteerS

Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss

Bioequivalence Study of Denosumab CP4 Drug Product and Commercially Available Denosumab CP2 Drug Product

Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids

A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis

Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis

Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis

A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis

Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis

Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis

Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption

Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer

Effects of Denosumab on the Pharmacokinetics of Etanercept

Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis

Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab